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ABSTRACT
In space, astronauts are exposed to a large doses of ionizing radiation which can
cause various health problems. The drug delivery of antioxidants and anti-inflammatory
substances is a promising countermeasure for the harmful cellular effects of radiation
exposure. Curcumin is a polyphenol derived from the rhizome of the turmeric plant that
has strong antioxidant capabilities. The therapeutic potential of this radical scavenging
drug is limited by poor uptake in the body due to its insolubility in water, rapid
metabolism by the intestinal mucosa and liver, and quick excretion. Drug delivery
vehicles can be used to enhance the bioavailability of curcumin. Albumin, a
biodegradable and non-immunogenic plasma protein, can be utilized as a drug delivery
vehicle. Curcumin binds to albumin’s hydrophobic pockets, which increases its solubility
and decreases its rate of degradation in physiological conditions. Curcumin was
solubilized with 0.5% (w/v) fatty acid free human serum albumin (FAF HSA) and spray
dried to form a dry powder of particles. To produce particles with a smooth and spherical
morphology, 0.05% (v/v) Tween® 20 was included in the solution. Curcumin release
from these particles followed a first-order release profile (Ct/Cinf = 1 - ekt, t = time in min)
with k = 0.065 ± 0.003.
To alter the release of curcumin from the spray dried particles, 0.5% FAF HSA was
crosslinked using 0.01M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and 5 mM Nhydroxysulfosuccinimide. This crosslinking method was confirmed by native
polyacrylamide gel electrophoresis (PAGE) and differential scanning calorimetry (DSC).
For the native PAGE results, multiple protein bands at high molecular weights were
observed for the crosslinked FAF HSA and a single protein band for the uncrosslinked
v

FAF HSA. This suggested that multiple FAF HSA molecules had been crosslinked to
each other. DSC results reported a significant increase in melting point from 53.60 ± 1.35
°C to 63.82 ± 2.34 °C of spray dried FAF HSA particles, further confirming the
crosslinking method. Curcumin was bound to the crosslinked FAF HSA in the presence
of 0.05% Tween® 20 and spray dried. The resulting particles showed a less uniform
morphology and curcumin release followed a first-order profile with a significantly lower
k = 0.049 ± 0.004. Future work to improve the morphology of the crosslinked FAF HSA
particles and increase the level of crosslinking to further slow curcumin release will
enhance the applicability of these particles in mitigating radiation-induced cell damage.
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SSE
sulfo-NHS
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= differential scanning calorimetry
= 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide
= extra-high tension
= fatty acid free
= human serum albumin
= molecular weight cutoff
= polyacrylamide gel electrophoresis
= phosphate buffered saline
= standard error of the mean
= sum of squared errors of prediction
= N-hydroxysulfosuccinimide
= Tween® 20, for electrophoresis
= ultraviolet-visible
= wavelength
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I. INTRODUCTION

A. Background
Astronauts are exposed to increased levels of ionizing radiation while in space. With
this increased exposure comes a multitude of health risks including the potential to
develop cancer (Durante and Cucinotta, 2008). TABLE I outlines approximations for
radiation doses experienced during space flight as compared to radiation doses
experienced on Earth during the same period of time (Cucinotta and Durante, 2006; Rask,
2008). As can be seen, protection from radiation becomes increasingly important as
missions become longer and take humans deeper into space. The development of
effective countermeasures is critical to advancing human deep space exploration.
There are three main methods for limiting exposure to ionizing radiation. The first is
to move further away from the radiation source. This is not possible in space because
space radiation is omnidirectional. The second way to reduce exposure is to decrease the
exposure time, but manned missions will only get longer as humans travel farther away
from Earth to other planets, asteroids, and beyond. The last method for limiting exposure
to ionizing radiation is shielding. Though plausible, the additional mass from the
shielding would likely exceed current launch capabilities. Attempts are made to minimize
harm via strategic launch schedules and astronaut selection of individuals with lower
susceptibility to the effects of radiation exposure (Cucinotta and Durante, 2009).

11

TABLE I
OBSERVED RADIATION DOSE FOR VARIOUS SPACE TRAVEL MISSIONS
Mission Type
Apollo 14
(9-day mission to the Moon)
International Space Station Mission
(up to 6 months orbiting Earth at
353 km)
Estimated Mars Mission
(3 years)

Mission
Radiation Dose
11.4 mSv

Terrestrial Radiation Dose
(3.6 mSv/year)
0.09 mSv

160 mSv

1.8 mSv

1,200 mSv

10.8 mSv

Radiation can cause damage to cellular components through direct energy transfer or
indirect production of free radicals from water molecules (Cucinotta and Durante, 2009).
Cellular damage is followed by an inflammatory response. Most chronic diseases are the
result of chronic dysregulation of the inflammatory response (Aggarwal, 2007). Since
exposure to radiation during space travel is currently unavoidable, countermeasures that
work to oppose these harmful effects become increasingly important. The development of
delivery systems for antioxidant and anti-inflammatory drugs is one such
countermeasure.
Curcumin (diferuloylmethane) is a highly active polyphenol component of Curcuma
longa (commonly known as turmeric), an herb frequently used as a food additive and
preservative. It comes from the dried rhizome of the turmeric plant, and demonstrates
chemopreventative activities as a result of its antioxidant and anti-inflammatory
properties. Curcumin is a good scavenger of free radicals. Additionally, it can inhibit
expression or suppress production of pro-inflammatory markers (Anand et al., 2007). It
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does not show toxicity and has been safely tested at dosage levels of 8 g/day in humans
(Cheng et al., 2001).
The therapeutic potential of curcumin is limited by its poor bioavailability. These
bioavailability limitations can be attributed to curcumin’s virtual insolubility in biological
fluids and rapid degradation at physiologic pH (Hatcher et al., 2008; Sharma et al., 2005).
The oral intake of 3.6 g of curcumin, has been shown to peak serum curcumin levels at
11.1 nmol/L after one hour of dosing (Sharma et al., 2004). At physiologic pH, curcumin
degradation into feruloylmethane and vanillin occurs within 30 minutes (Lin et al., 2000).
Intravenous administration of curcumin would be a preferred route of delivery
because it would allow curcumin to bypass rapid degradation by the intestinal mucosa
(Anand et al., 2007). For this administration to work, curcumin’s solubility in biological
fluids would need to be addressed, and solvent-based delivery vehicles are one approach
for doing so (Fu et al., 2009). Nanoparticles are often used in solvent-based delivery
vehicles because they allow for controlled drug release to happen over time and with a
predictable profile.
Albumin (molecular weight: 67 kDa, melting point: approximately 62 °C) is the
most abundant human plasma protein. Because it is stable at physiological conditions,
readily soluble, nontoxic, and nonimmunogenic, albumin is a commonly used drug
delivery vehicle (Atala and Lanza, 2002; Michnik et al., 2006). For example, nanoparticle
albumin-bound paclitaxil was approved by the Food and Drug Administration in 2006 to
treat metastatic breast cancer (Fu et al., 2009). The molecular structure of albumin
(FIGURE 1) consists of six subdomains and six sites for binding fatty acids (Pulla Reddy
et al., 1999; Sugio et al., 1999). These sites can serve as pockets that bind hydrophobic
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drugs such as curcumin, allowing them to become solubilized and protecting them from
degradation, improving their bioavailability. Albumin has been shown to bind curcumin
with 2:1 stoichiometry (Pulla Reddy et al., 1999).

FIGURE 1 - Schematic drawing of HSA (Sugio et al., 1999)

Techniques such as emulsification, desolvation, and thermal gelation have all been
used to produce albumin nanoparticles (Elzoghby et al., 2012). Spray drying, another
technique, is commonly used in the pharmaceutical industry to produce dry particles from
liquids (FIGURE 2). Spray drying can be performed using water as the solvent, making it
an advantageous approach. When spray drying with a Nano Spray Dryer, a piezoelectric
actuator is driven at an ultrasonic frequency, generating vibrations that direct the
injection of the liquid phase into an array of micron-sized holes. These holes form
consistently-sized droplets that fall down a column under high pressures, quickly drying
14

the droplets into dry particles. These particles are collected at the bottom of the column
using an electrostatic precipitator. The method of spray drying is advantageous for
albumin-based drug delivery because it is able to make compact particles with
reproducible size, surface morphology, and release characteristics (Elzoghby et al.,
2012).

FIGURE 2 - Schematic of spray drying process (Lee et al., 2011)
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B. Previous Work
Initial experiments were conducted to optimize curcumin solubility by binding it to
various forms of albumin (CEW, BSA, and FAF BSA). Each type of albumin was
examined at various concentrations (5%, 1%, and 0.1% w/v) in DI water. With each type
of albumin, the increasing albumin concentrations resulted in increasing solubility of
curcumin (FIGURE 3). After comparing the three types of albumin, statistical analysis
showed that FAF BSA was able to solubilize the most curcumin.

FIGURE 3 - Curcumin binding to CEW, BSA, and FAF BSA at various albumin
concentrations.
For spray drying studies, HSA was used given the therapeutic applications of
albumin-curcumin particles in humans. Since FAF BSA was shown to bind more
curcumin than BSA, FAF HSA was the type of albumin selected for particle fabrication.
FAF HSA-curcumin solutions were made with various albumin concentrations (0.1%,
0.5%, and 1% w/v) in DI water and then spray dried to form particles with a Buchi Nano
16

B-90 spray dryer (head temperature of 120 oC, pressure of 45 hPa, drying gas flow rate of
150 L/min, peristaltic pump setting of 1, and mesh containing 4µm holes). To aid in
particle formation, T20 (0.05% v/v) was added to the FAF HSA solutions prior to mixing
with curcumin (Lee et al., 2011).
With increased FAF HSA concentrations, there was an increase in the average
particle size. By using dynamic light scattering, it was determined that the average
particle size ranged from 369 ± 180 nm for 0.1% FAF HSA-curcumin particles to 481 ±
200 nm for 1% FAF HSA-curcumin particles. The 0.5% FAF HSA concentration was
chosen as the concentration to produce spray dried particles that balanced smaller particle
size with more curcumin binding. The T20 addition to 0.5% FAF HSA-curcumin
produced particles with a more smooth and spherical morphology as shown in the
scanning electron microscope images in FIGURE 4.

With T20

Without T20

FIGURE 4 - Scanning electron microscope images of 0.5% FAF HSA-curcumin particles
without and with 0.05% (v/v) T20 (Zeiss Evo, 20 kV, SE1 detector, sputter coated with
gold/palladium for five minutes).
17

Curcumin release from FAF HSA particles was examined over time and the release
profile best fit a first-order (Ct/Cinf = 1 – e-kt, t = time) release. The protocol was adapted
from Jithan et al., 2011. The release of curcumin from 2 mg/ml of 0.5% FAF HSAcurcumin particles reached a saturation level in approximately 1 hour and followed the
first-order model of Ct/Cinf = 1 – e-0.055t.

C. Albumin Crosslinking
Spray drying particles of albumin with bound curcumin allows for the production of
particles with release characteristics that can be manipulated by using various production
parameters or solution composition. The crosslinking of albumin was explored as a
means for prolonging the release of bound curcumin because crosslinked albumin
particles may need more time to solubilize and release curcumin. Additionally, the
crosslinks on these albumin particles may extend the time needed for enzymatic
breakdown once the particles enter a cell, prolonging the release of bound curcumin.
Three main crosslinking agents were considered – glutaraldehyde, BS3, and EDC.
These three crosslinking agents were initially chosen because of their solubility in water.
Glutaraldehyde is commonly used as a fixative because of its aggressive protein
crosslinking ability (Migneault et al., 2004). Though effective, glutaraldehyde has been
classified as a skin, eye, and respiratory irritant (National Toxicology Program, 1999).
BS3 is a homobifunctional crosslinking agent that reacts with primary amines such as
those found on lysine residues or the N-terminus of a polypeptide (Huang et al., 2004). It
can perform its crosslinking procedure at physiologic conditions, but its cytotoxicity is
still unknown. EDC is a zero-length crosslinker that crosslinks carboxylic acids to
18

primary amines. Thus, there are 187 potential EDC crosslinking sites (lysine, arginine,
glutamic acid, and aspartic acid residues, one polypeptide N-terminus, and one
polypeptide C-terminus) per molecule of HSA, however there are two lysines located on
the molecular surface (Sugio et al., 1999). Additionally, no significant cytoxicity has
been observed with EDC crosslinking (Park et al., 2002). Sulfo-NHS is also watersoluble and is often used in conjunction with EDC to improve its crosslinking ability by
creating stable amine-reactive intermediates (FIGURE 5) (Hermanson, 2013). The
advantages of the EDC/sulfo-NHS mechanism made it an ideal method to crosslink
albumin for spray dried particle production. The crosslinking of albumin with EDC has
not been previously explored for spray dried particles.

FIGURE 5 - Crosslinking mechanism for EDC with sulfo-NHS (Hayworth, 2014)

19

D. Objective
The objective of this was work was to alter the release profile of curcumin from
spray dried albumin particles by crosslinking albumin with EDC and sulfo-NHS. To
achieve this goal, this work covalently crosslinked albumin using EDC and sulfo NHS,
spray dried the crosslinked albumin to form particles, and characterized particle size,
morphology, curcumin loading capacity, and release kinetics.

20

II. METHODS

A. Crosslinking Albumin with Glutaraldehyde
Initially, 0.5% (w/v) BSA in DI water was crosslinked using glutaraldehyde at 100:1
and 15:1 glutaraldehyde:BSA molar ratios (Fuguet et al., 2007). Crosslinking was
conducted on an orbital shaker for 24 hours at room temperature (20°C – 25°C) in a 50
mL centrifuge tube. The solution was dialyzed in DI water for 24 hours to removed
excess glutaraldehyde.

B. Crosslinking Albumin with EDC and Sulfo-NHS
A second crosslinking method was also explored. The crosslinking protocol was
adapted from Bioconjugate Techniques (Hermanson, 2013), and it crosslinked FAF HSA
(SeraCare Life Sciences) using EDC (Acros Organics) and sulfo-NHS (Aldrich
Chemistry). For this process, a final concentration of 0.01M EDC in DI water and 5mM
sulfo-NHS in DI water were used to crosslink 0.5% (w/v) FAF HSA in DI water (7.5 x
10-5 M). This solution was deemed a “1x” level of crosslinking based on the amount of
EDC that was added. An EDC concentration of 0.1 M was used to crosslink at the 10x
level (n = 1). The crosslinking process was conducted for 24 hours on an orbital shaker at
room temperature in a 50 mL centrifuge tube. Based on the molar ratio of EDC to FAF
HAS for the 1x conditions listed above, 134 crosslinks could be theoretically formed.
Upon completion of crosslinking, by products of the crosslinking reactions and
excess crosslinking reagents were removed via dialysis using 3500 MWCO dialysis
tubing (Spectra/Por 7 Dialysis Membrane, Pre-treated RC Tubing). Prior to dialysis, the
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membrane was rinsed thoroughly with DI water and allowed to soak in DI water for
thirty minutes. Fifteen minutes into this soaking period, the DI water was replaced with
fresh DI water. The crosslinked FAF HSA solution was dialyzed in 4 L DI water for 24
hours at room temperature. After the first 24 hours of dialysis, the DI water was replaced
with 4 L of fresh DI water. The dialysis was continued for another 24 hours.

C. Particle Fabrication by Spray Drying
Spray drying was performed using the Buchi Nano Spray Dyer B-90 at a head
temperature of 120 °C, drying gas flow rate of 150 L/min (Lee et al., 2011), peristaltic
pump setting of 2 (pump rotation at double the standard speed), and mesh containing
4µm holes . The sample being sprayed was kept on ice and covered in foil. The spray
dried particles were collected by scraping them off of the collecting drum onto weigh
paper in a chemical hood. These particles were placed in a centrifuge tube wrapped in foil
and stored at -20 °C for 1 day. The same conditions were used for spray drying all
conditions unless noted.

D. Confirmation of Albumin Crosslinking
The crosslinking of FAF HSA with EDC and sulfo-NHS was confirmed using two
different methods. The first method used to confirm FAF HSA crosslinking was native
PAGE. This method used an electrical charge to pull proteins through a polyacrylamide
gel achieving separation based on molecular weight and geometry (both would be altered
by crosslinking albumin). The Bio-Rad Mini-PROTEAN Tetra System was used with
7.5% precast polyacrylamide gels. Buffers were made according to the adapted
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formulations provided in TABLE II from Bio-Rad Laboratories, Inc. Solutions of FAF
HSA (n = 4) and 1x FAF HSA (n = 4) in DI water were made. The gel was loaded with 8
µg of regular FAF HSA or 1x FAF HSA (as determined by absorbance at λ = 280 nm)
per well at a 1:1 volume ratio with the Native PAGE sample buffer for a total loading
solution volume of 40 µL. Additionally, one lane was loaded with 9µL of the Bio-Rad
Precision Plus Unstained Protein Standard, 1 µL of β-mercaptoethanol (Sigma), and 30
µL of Native PAGE running buffer. Lanes not used with samples were loaded with 40 µL
of Native PAGE running buffer. The loaded gel was run in the Tetra System at 100 V and
4 °C for 1.5 hours with the Bio-Rad PowerPac Basic serving as the voltage source. Upon
completion of this run, the gel was removed from its casing and stained using Coomassie
Brilliant Blue R-250 Staining Solution (Bio-Rad) at room temperature while on a rocker
for 3 hours. The polyacrylamide gel was then exposed to Coomassie Brilliant Blue R-250
Destaining Solution (Bio-Rad) at room temperature with rocking for 12 hours. A digital
image of the gel was captured. Destaining continued for another 13 days. On day 14,
another digital image of the gel was captured.
TABLE II
NATIVE PAGE BUFFER FORMULATIONS
Native PAGE
Running
Buffer
Native PAGE
Sample Buffer

0.5M TrisHCl

1.5g Trizma Base (Sigma Life Science)
7.2g Glycine (Sigma Life Science)
500mL DI Water
0.5mL of 0.5M Tris-HCl, pH 6.8
1.1mL Glycerol (Sigma-Aldrich)
0.04mL of 1% Bromophenol Blue
1.86mL DI Water
6.06g Trizma Base
~60mL DI Water
Total Volume = 100mL

23

Adjust to pH 6.8 with
HCl (Sigma). Make to
100mL with DI Water.

1%
Bromophenol
Blue

100mg Bromophenol Blue (Sigma-Aldrich)
10mL DI Water

The second method employed DSC (TA Instruments, Auto Q20) to compare the
melting points of spray dried FAF HSA between its uncrosslinked and 1x crosslinked
forms. DSC reports the heat flow (W/g) needed to maintain a steady increase in
temperature for a sample of known mass. The DSC was calibrated with indium across a
temperature range of 20 °C to 100 °C using a ramp rate of 2 °C/min and nitrogen flow
rate of 50 mL/min. The FAF HSA samples were prepared in solution with DI water, and
as spray dried particles. The samples were placed in aluminum pans (TA Instruments,
Standard Pan and Lid) and heated in the DSC from 20 °C to 100 °C using a ramp rate of
2 °C/min and nitrogen flow rate of 50 mL/min. An empty aluminum pan was
simultaneously heated in the DSC as a reference. Melting points were determined by
finding the endothermic peaks of the DSC curves (heat flow v. temperature) over the
range of 20 °C to 100 °C using the Q90 Universal Analysis software (TA Instruments).
For the DSC melting point results from spray dried FAF HSA and 1x FAF HSA, one
sample was spray dried for each condition. Five aliquots of the FAF HSA sample and
four aliquots of the 1x FAF HSA sample were measured. Results are reported as average
± SEM °C. Statistical significance was determined by conducting a t-test (Microsoft
Excel) with unequal variances and α = 0.05 on these measurements.

E. Curcumin Binding
For the testing conditions with curcumin, 2.5 mg/ml curcumin (Sabinsa) and 0.05%
(v/v) T20 (Sigma) were added to the 1x FAF HSA in DI water after dialysis was
24

complete. Due to curcumin’s sensitivity to light, the solution was wrapped in aluminum
foil once curcumin was added. The solution was placed on an orbital shaker for 24 hours
at 4 °C. Curcumin was bound to FAF HSA in the presence of T20 using this same
procedure.
After curcumin was allowed to bind to 1x FAF HSA-T20 and FAF HSA-T20,
excess unbound curcumin was removed via centrifugation (Beckman Coulter Allegra 6R
Centrifuge). The solutions were centrifuged at 3750 rpm (3210 x g based on Equation 1;
rotational radius, r = 20.4 cm) and 4 °C for 20 minutes. The unbound curcumin formed a
pellet during this centrifugation. The supernatants were removed and centrifuged again at
3210 x g and 4 °C for another 20 minutes. The supernatant solutions were wrapped in
aluminum foil.

g Force = (rpm)ଶ × 1.118 × 10ିହ × r

(1)

F. Quantification of Curcumin Bound to Albumin
A standard curve was generated with curcumin initially dissolved in DMSO (Sigma
Life Science) at a concentration of 5mM. UV-vis absorbance measurements were
collected of a 0.125 mM curcumin solution that was created by diluting the 5mM
curcumin in 0.5% FAF HSA in DI water with 0.05% T20. This solution was serially
diluted in 0.5% FAF HSA in DI water with 0.05% T20 and vortexed to generate the
standard curve. These measurements were blanked with a solution containing 50 µL of
DMSO in 1.95 mL of 0.5% FAF HSA in DI water with 0.05% T20.
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To determine the concentration of bound curcumin, supernatant absorbance was
quantified using UV-visible spectroscopy (Thermo Scientific NanoDrop 2000c
Spectrophotometer) at a wavelength of λ = 425 nm (the peak absorbance of curcumin) for
solutions of FAF HSA-T20-curcumin (n = 3) and 1x FAF HSA-T20-curcumin (n = 3).
Results are reported as average ± SEM µM curcumin. Statistical significance was
determined by conducting a t-test (Microsoft Excel) with unequal variances and α = 0.05
on the absorbance readings for the FAF HSA-T20-curcumin and 1x FAF HSA-T20curcumin solutions.
Measurements were also collected for negative control conditions of FAF HSA-T20
(n =1) and 1x FAF HSA-T20 (n = 1) in DI water. Three measurements were taken for
each of these samples, and the reported values for curcumin binding are the average ±
SEM µM curcumin of these three measurements. Molar ratios of bound curcumin to FAF
HSA were calculated using Equation 2.

x=

(ୠ୭୳୬ୢ ୡ୳୰ୡ୳୫୧୬ ୧୬ ஜ)൫ଵషల ൯

ై

ቀହ ୭  ୌୗቁቀ

భౣౢ
ቁ
లళ,బబబ 

; Bound Curcumin:FAF HSA = x:1

(2)

G. Characterization of Particles
Particle size and morphology were characterized using scanning electron
microscopy for FAF HSA-T20-curcumin (n = 3) and 1x FAF HSA-T20-curcumin (n = 3)
particles. Particles were sprinkled onto carbon tape on pegs that were sputter coated with
gold/palladium at 0.1 torr and 5mA for 4 minutes. Particles were visualized with a Zeiss
Supra 35VP scanning electron microscope using a secondary electron detector with EHT
= 2.0 kV. Three images were captured for each sample. Particle size was measured using
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ImageJ software developed by the National Institutes of Health (Rasband, 1997). The
scale bar on the original image was used to calibrate the dimensions of the image pixels.
The long axis of each particle whose full diameter was visible was measured and
considered the particle diameter. Particles with smooth and spherical morphology were
counted for each image, and these counts were normalized to the magnification of 54703
X (27.5 µm2 image area). Results are reported as average ± SEM. Statistical significance
was determined by conducting a t-test (Microsoft Excel) with unequal variances and α =
0.05 on the size and morphology measurements for FAF HSA-T20-curcumin and 1x FAF
HSA-T20-curcumin particles. Images and measurements were also collected for negative
control conditions of FAF HSA-T20 (n =1), 1x FAF HSA (n = 1) and 1x FAF HSA-T20
(n = 1) particles. Three measurements were taken for each of these samples, and the
reported values are the average ± SEM of these three measurements.

H. Profiling Curcumin Release
Curcumin release from FAF HSA-T20-curcumin (n = 3) and 1x FAF HSA-T20curcumin (n = 3) spray dried particles over time was profiled via differential extraction
and UV-visible spectroscopy (Jithan et al., 2011; O’Toole et al., 2012). For differential
extraction, the particles were added to 1% L-ascorbic acid (Sigma) in PBS (Fisher
BioReagents) to make the aqueous layer. The solution was mixed via inversion of the
tube, and then an equivalent volume of 0.1% BHT (Aldrich) in octanol (Sigma-Aldrich)
was gently added to serve as the organic layer. Particles were added at a concentration of
2 mg/mL based on the total volume of the aqueous and organic layers. Upon release from
the particles, curcumin was pulled into the organic layer because of its hydrophobicity.
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The absorbance of this organic layer was measured by using UV-visible spectroscopy
(Thermo Scientific NanoDrop 2000c Spectrophotometer) at a wavelength of λ = 425 nm.
Spectral scans indicated that this was the peak absorbance for curcumin in octanol. The
release study was considered complete once the absorbance readings from three
consecutive time points confirmed a plateau for curcumin release. Curcumin
concentration was calculated using a standard curve of curcumin in 0.1% BHT in octanol
(2500 mM to 2.5 mM). Each solution was vortexed prior to collecting the absorbance
readings. All readings were blanked with 0.1% BHT in octanol. As negative controls,
release studies were also conducted with FAF HSA-T20 (n = 1) and 1x FAF HSA-T20 (n
= 1) particles.
Raw curcumin release concentrations were converted to ratios of total released
curcumin (Ct/Cinf). For each measurement, the curcumin concentrations of the final three
time points were averaged and represented maximum curcumin release (Cinf). Curcumin
concentrations for the earlier time points (Ct) were divided by this Cinf. Ct/Cinf became the
dependent variable used to fit curcumin release profiles to the first-order mathematical
model. First-order models were generated using Minitab 16 statistical analysis software.
SSE was used as an indicator of fit for the first-order model. Statistical significance was
determined by conducting a t-test with unequal variances (Microsoft Excel, α = 0.05) on
the sample k terms output for the first-order models of curcumin release from FAF HSAT20-curcumin (n = 3) and 1x FAF HSA-T20-curcumin (n = 3) particles.
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I. Additional Experiments
Additional studies were conducted to explore methods for optimizing the
crosslinked FAF HSA spray dried particles. 1x FAF HSA (n = 1) in DI water was made
with double the concentration of T20 (0.1%) to observe changes in particle morphology
via scanning electron microscopy. Additionally, spray drying was attempted with a 2.5x
FAF HSA-T20 solution (n = 1).
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III. RESULTS AND DISCUSSION

A. Crosslinking Albumin with Glutaraldehyde
BSA crosslinked with glutaraldehyde at 100:1 glutaraldehyde:BSA formed a gellike substance that could not be spray dried through the small diameter (4µm) holes in the
spray drying mesh without causing clogging. The 15:1 glutaraldehyde:BSA appeared to
have a lower viscosity that perhaps could have been spray dried. However,
glutaraldehyde toxicity remained a concern for the therapeutic potential of spray dried
particles made from this crosslinking technique (Atala and Lanza, 2002). An alternative
method for crosslinking was simultaneously pursued to overcome some of the hurdles
associated with the glutaraldehyde technique.

B. Crosslinking Albumin with EDC and Sulfo-NHS
FAF HSA was crosslinked in DI water at various levels ranging from 1x to 10x
based on the concentration of EDC used for the crosslinking. It was found that the 10x
level of crosslinking produced a gel-like solution of crosslinked FAF HSA that was not
able to be spray dried. The 1x crosslinked FAF HSA was able to be spray dried without
clogging the spray mesh. Unless noted differently, the 1x condition was used in the
subsequent studies to confirm FAF HSA crosslinking, characterize the particles, and
profile curcumin release from the particles.
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C. Confirmation of Albumin Crosslinking
1. Native PAGE
Crosslinking of FAF HSA with EDC and sulfo-NHS was confirmed using Native
PAGE. The digital image of the gel during the destaining process at the 12 hour time
point (FIGURE 6A) showed the bands of FAF HSA near the 75 - 50 kDa range with
some smearing. Destaining was continued to reduce the smearing in the FAF HSA
samples. The digital image of the destained gel at the 14 day time point (FIGURE 6B)
confirmed that the bands of FAF HSA were in the 75 - 50 kDa range. The gel lanes
loaded with 1x FAF HSA contained multiple bands at molecular weights above the
molecular weight of FAF HSA. These bands represented multiple FAF HSA units being
crosslinked to one another, forming larger globules of FAF HSA that had an altered
geometry and increased molecular weight. The difference in protein band profiles for the
FAF HSA and 1x FAF HSA confirmed that FAF HSA was crosslinked.

FIGURE 6 - Coomassie-stained native PAGE gel after (A) 12 hours and (B) 14 days of
exposure to destain solution. From left to right in each image, the first lane was loaded
with the molecular weight protein standard (MW). The next lane was loaded with running
buffer only. The third lane was loaded with 1x FAF HSA, and the fourth lane was loaded
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with FAF HSA. The conditions for the third and fourth lanes were repeated for the
remaining lanes.

2. DSC
The melting point of FAF HSA in DI water was compared to the melting point of 1x
FAF HSA in DI water. These results did not consistently generate distinguishable
endothermic peaks. Most likely, there was too low a concentration of FAF HSA present
in the solutions to produce repeatable results. Lyophilized FAF HSA from the supplier
generated endothermic peaks at 72.74 ± 2.68 oC. The lyophilized 1x FAF HSA gave
inconsistent results.
Given that the final product being explored was FAF HSA in its spray dried form,
melting points for spray dried FAF HSA particles were compared to the melting points of
spray dried 1x FAF HSA particles using DSC. Reproducible and distinguishable
endothermic peaks were identified (TABLE III). The 1x FAF HSA particles had a
melting point of 63.82 ± 2.34 oC, which was significantly higher (p = 0.0128) than the
melting point of 53.60 ± 1.35 oC for the FAF HSA particles. With the additional bonds
formed via crosslinking, an increase in the amount of energy needed to break these bonds
and melt crosslinked FAF HSA was expected. Consequently, the higher melting point
observed for 1x FAF HSA particles supported the Native PAGE conclusion that FAF
HSA was crosslinked with the EDC/sulfo-NHS. Representative DSC curves are shown in
FIGURE 7 to illustrate the shift in melting point between FAF HSA particles and 1x FAF
HSA particles.
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TABLE III
DSC RESULTS FOR FAF HSA PARTICLES V. 1x FAF HSA PARTICLES
Melting Point
(oC)

Raw Data
average ± SEM (oC)
1
53.60 ± 1.35 *
FAF HSA 55.60, 51.03, 57.76, 50.76, 52.87
2
63.82 ± 2.34 *
1x FAF HSA 57.68, 64.79, 63.82 , 69.00
1,2
The DSC curves for these measurements are depicted in FIGURE 7.

Representative DSC Results for
FAF HSA and 1x FAF HSA Spray Dried Particles
FAF HSA

-0.165

1x FAF HSA

Heat Flow (W/g)

-0.185
-0.205
-0.225

*

-0.245
-0.265

*
-0.285
-0.305
30

40

50
60
Temperature (°C)

70

80

FIGURE 7 - Representative DSC endothermic peak of 1x FAF HSA was shifted to the
right from FAF HSA, which indicated a higher melting temperature for 1x FAF HSA.
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D. Quantification of Curcumin Bound to Albumin
The concentration of curcumin bound to FAF HSA-T20 in DI water as measured
prior to spray drying was 115.551 ± 6.918 µM. This was calculated to be a molar ratio of
approximately 1.55:1 for curcumin:FAF HSA. The concentration of curcumin bound to
1x FAF HSA-T20 in DI water as measured prior to spray drying was 114.316 ± 9.970
µM. This was calculated to be a molar ratio of approximately 1.53:1 for curcumin:FAF
HSA. As negative controls, FAF HSA-T20 and 1x FAF HSA-T20 exhibited negligible
readings at 425 nm. Even though FAF HSA was crosslinked, these crosslinks did not
significantly reduce curcumin binding (p = 0.9185) to the FAF HSA (FIGURE 8).

Bound Curcumin Concentration (µM)

Bound Curcumin Concentrations for
FAF HSA-T20 and 1x FAF HSA-T20 Solutions
120
100
80

FAF HSA-T20
FAF HSA-T20-Curc

60

1x FAF HSA-T20
40

1x FAF HSA-T20-Curc

20
0

Solution Type

FIGURE 8 - Concentrations of curcumin bound to FAF HSA-T20 and 1x FAF HSA-T20
in DI water.
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Characterization of Particles
1. Morphology
Scanning electron microscopy images of the various spray dried particles are shown
in TABLE IV. FAF HSA-T20 and FAF HSA-T20-curcumin particles showed spherical
and smooth morphologies. Since the release of curcumin from spray dried albumin
particles is affected by variations in particle shape and surface morphology, this spherical
shape and uniform surface morphology was desirable. The 1x FAF HSA-T20 particles
were not consistently spherical and smooth as observed with the FAF HSA-T20 particles
produced under the same conditions. The 1x FAF HSA particles showed a wrinkled
morphology that became smoother in the presence of T20 (this was also seen with FAF
HSA, Lee et al., 2011). The counts of particles with smooth and spherical morphology
per 27.5 µm2 area for FAF HSA-T20-curcumin were (55.5 ± 9.8) and 1x FAF HSA-T20curcumin (14.0 ± 2.1) (TABLE V). Even though differences in morphology were
observed between these conditions, the difference was not statistically significant (p =
0.0541).
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TABLE IV
SCANNING ELECTRON MICROSCOPY IMAGES OF SPRAY DRIED PARTICLES

No T20,
No
Curcumin

FAF HSA
-----

1x FAF HSA

T20, No
Curcumin

T20,
Curcumin

2. Size
The results for spray dried particle diameters are outlined in TABLE V. Theoretical
calculations report the minimum viable diameter for human capillaries to be
approximately 4 µm (Freitas, 1999) – an important upper size limit for the potential
intravenous administration of these particles. The observed particle diameters fell well
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below this upper size limit. No statistical significance was observed between diameters
for the FAF HSA-T20-curcumin particles and the 1x FAF HSA-T20-curcumin particles.
Therefore, crosslinking 0.5% FAF HSA with EDC and sulfo-NHS did not result in a
significant change of particle diameter (p = 0.9889).

TABLE V
SIZE AND MORPHOLOGY MEASUREMENTS FOR SPRAY DRIED PARTICLES.

FAF HSA-T20
FAF HSA-T20-Curcumin
1x FAF HSA-T20
1x FAF HSA-T20-Curcumin

Smooth and Spherical
Particles
56.8 ± 7.2
55.5 ± 9.8
4.4 ± 1.4
14.0 ± 2.1

Diameter (nm)
618.552 ± 14.837
713.994 ± 25.723
742.095 ± 43.087
712.938 ± 65.292

E. Profiling Curcumin Release
1. Raw Curcumin Release Data
The absorbance spectral scans shown in FIGURE 9 confirmed that curcumin’s peak
absorbance occurred at λ = 425 nm for these release studies. Curcumin release data for
FAF HSA-T20 versus FAF HSA-T20-curcumin particles is shown in FIGURE 10. The
Cinf for the FAF HSA-T20-curcumin particles was 137.796 ± 7.330 µM, and the Cinf for
the 1x FAF HSA-T20-curcumin particles was 146.957 ± 5.414 µM. As negative controls,
FAF HSA-T20 and 1x FAF HSA-T20 particles showed negligible absorbance at 425nm.
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A

B

FIGURE 9 - Representative spectral scans for absorbance of organic layer from release
study of FAF HSA-T20-curcumin (A) and 1x FAF HSA-T20-curcumin (B) spray dried
particles at 180 minutes.
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2. Fitting of Curcumin Release Model
FIGURE 10 shows an overlay of the average release profiles of FAF HSA-T20curcumin and 1x FAF HSA-T20-curcumin particles for comparison. The k values
determined from the first order fits to FAF HSA-T20-curcumin particles were 0.065 ±
0.003 and 1x FAF HSA-T20-curcumin particles was 0.049 ± 0.004. The release profile
from 1x FAF HSA-T20-curcumin particles had a significantly (p = 0.0339) lower k than
from FAF HSA-T20-curcumin particles, which implied a slower release.
FIGURE 11 shows the first-order models generated by Minitab software. Curcumin
release from the FAF HSA-T20-curcumin particles had an SSE of 0.0006. Curcumin
release from the 1x FAF HSA-T20-curcumin particles had an SSE of 0.0022. The low
SSE values for both of these first-order models indicated that the first-order model was a
good fit to the data and exploration of other release models was not needed.
Based on the first-order models that were generated, it took approximately 10.7
minutes for 50% of the maximum curcumin release to occur for the FAF HSA-T20curcumin particles as compared to approximately 14.1 minutes for the 1x FAF HSA-T20curcumin particles. It took approximately 46.1 minutes and 61.1 minutes for 95% of the
maximum curcumin release to occur for the FAF HSA-T20-curcumin and 1x FAF HSAT20-curcumin particles, respectively. This illustrates the slowed curcumin release from
the crosslinked particles.
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Curcumin Release from Spray Dried
FAF HSA-T20 and 1x FAF HSA-T20 Particles

Curcumin Released (Ct/Cinf)

1.1

0.9

0.7

0.5

0.3

0.1

-0.1

0

50

100

150

200

250

Time (min)
FAF HSA-T20

FAF HSA-T20-Curcumin

1x FAF HSA-T20

1x FAF HSA-T20-Curcumin

FIGURE 10 - Curcumin release data for FAF HSA-T20, FAF HSA-T20-curcumin, 1x
FAF HSA-T20, and 1x FAF HSA-T20-curcumin spray dried particles.
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Fitted Line Plot
Curcumin Release (Ct/Cinf) = 1 - exp(-'Time (min)' * 0.0649729)

A
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Time (min)
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Fitted Line Plot
Curcumin Release (Ct/Cinf) = 1 - exp(-'Time (min)' * 0.0486633)

B

1.1

Curcumin Release (Ct/Cinf)
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FIGURE 11 - Fitted line plot of first-order models for curcumin release from FAF HSAT20-curcumin (A) and 1x FAF HSA-T20-curcumin (B) spray dried particles generated
using Minitab software.
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F. Additional Experiments
By doubling the T20 that was added to 1x FAF HSA, the production of more
spherical and smooth spray dried particles was observed (TABLE VI). Spray drying of
2.5x FAF HSA-T20 was conducted without clogging of the spray mesh. Higher
concentrations of T20 improved the morphology of 1x FAF HSA particles, and the
feasibility of spray drying FAF HSA with increased levels of crosslinking was proven.

TABLE VI
SCANNING ELECTRON MICROSCOPY IMAGES OF 1X FAF HSA PARTICLES
WITH 0.05% T20 AND 0.1% T20
1x FAF HSA-0.05% T20

1x FAF HSA-0.1% T20
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IV. CONCLUSIONS, DISCUSSION, & RECOMMENDATIONS FOR FUTURE
WORK
This work produced crosslinked albumin particles with altered curcumin release
using the spray drying method. Crosslinking FAF HSA using EDC and sulfo-NHS was
confirmed using native PAGE and DSC. The native PAGE results showed multiple
protein bands for 1x FAF HSA as compared to the single band for uncrosslinked FAF
HSA. The protein bands for 1x FAF HSA were associated with higher protein molecular
weights than the single protein band for uncrosslinked FAF HSA, suggesting that
multiple FAF HSA molecules had been crosslinked to each other. DSC results reported a
significant increase of 10.22 °C in melting point for spray dried 1x FAF HSA particles as
compared to uncrosslinked FAF HSA particles, further confirming the crosslinking
method that was used.
Curcumin solubilization via binding to the 1x FAF HSA was not significantly
altered by the formation of the crosslinks in albumin. Therefore the loading efficiencies
of curcumin were the same for uncrosslinked and crosslinked albumin. The 1x FAF HSA
was then spray dried to form particles that were 712.938 ± 65.292 nm in diameter.
Crosslinking albumin did not alter the diameter of the particles formed by spray drying,
but the morphology of the particles was different when albumin was crosslinked.
The morphology of 1x FAF HSA particles was smoother with the addition of 0.05%
T20, but 1x FAF HSA-T20 and 1x FAF HSA-T20-curcumin particles did not exhibit the
same consistent spherical morphology as their FAF HSA-T20 and FAF HSA-T20curcumin counterparts. Counts for particles with smooth and spherical morphology were
not statistically significant. Still, the difference in observed particle morphology (TABLE
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IV) is of importance because it could contribute to altered curcumin release from 1x FAF
HSA-T20-curcumin particles. No significant difference in particle diameter was observed
for FAF HSA-T20-curcumin and 1x FAF HSA-T20-curcumin particles.
The release of curcumin from FAF HSA-T20-curcumin particles followed a firstorder release profile with the equation Ct/Cinf = 1-e-0.065t. The release of curcumin from 1x
FAF HSA-T20-curcumin particles followed a first-order release profile with the equation
Ct/Cinf = 1-e-0.049t. Statistical significance was observed between these two release profiles
with the curcumin release from 1x FAF HSA-T20-curcumin particles being slowed.
Further extending curcumin release from FAF HSA particles should be explored by
increasing the level of crosslinking. Crosslinking at a 2.5x level produced a solution that
could be spray dried (while stirring constantly). The upper limit of crosslinking that is
capable of being spray dried needs to be determined. Other techniques to form albumin
nanoparticles such as electrospraying and others listed in the introduction chapter will
need to be explored when the upper limit of crosslinking is reached.
The lower k value for the curcumin release from 1x FAF HSA-T20-curcumin
particles indicated prolonged curcumin release from these particles as compared to the
FAF HSA-T20-curcumin particles. In order to confirm that curcumin release is in fact
delayed for EDC crosslinked FAF HSA particles, particle morphology must be improved
to where smooth and spherical particles are consistently being produced via the spray
drying process. Previously collected data showed that the addition of T20 aided in
smooth albumin particle formation. Thus, one potential way to improve crosslinked
particle morphology would be to increase the concentration of T20 used. Other
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parameters that should be investigated include changing the pump setting to “normal”
speed and reducing the gas flow rate on the Buchi B-90 Nano spray dryer.
This work shows that crosslinking albumin with EDC and sulfo-NHS can produce
spray dried particles with slowed curcumin release. The cytotoxicity of the crosslinked
particles may be tested on cells in the future to show that they are non-toxic. The
bioactivity of curcumin released from crosslinked particles can be observed by testing the
viability of cancer cells treated with these particles. Curcumin delivery via spray dried
albumin particles shows promise and should continue to be explored.
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Soucy, P.A.; Jain, I; O’Toole, M.G; Fascioto, B.H.; Hoblitzell, P.J.; Keynton, R.S.; Ehringer, W.D.; Gobin, A.S.
Gamma Irradiation Protection from Low Doses of Curcumin.
Soucy, P.A.; Fasciotto, B.H.; O’Toole M.G.; Jain, I; Keynton, R.S; Ehringer, W.D.; Gobin, A.S.

POSTER PRESENTATIONS
Controlled Curcumin Release from Spray Dried Albumin Particles
KY EPSCoR Annual Conference
Increasing Curcumin Solubility via Spray Dried Albumin Particles
Biomedical Engineering Society Annual Meeting
Curcumin Delivery from Spray Dried Albumin Particles
Sullivan University Annual Nanotechnology Symposium
Space Suit Assembly Engineering at NASA Johnson Space Center
James Graham Brown Fellows Symposium
Coupled Human-Space Suit Mobility Testing
NASA Johnson Space Center Innovative Research & Design Poster Session
Curcumin Uptake and Effects on Gamma Irradiated Cells (2nd Author)
Biomedical Engineering Society Annual Meeting
Quantifying Overground Locomotion in Spinal Cord Injured Rats and Mice Using
Engineering Design Concepts
Research Louisville, won Engineering Collaboration Award
Curcumin Induced Death of Human Promyelocytic Leukemia Cells
University of Louisville Undergraduate Research Symposium
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Oct 2013
Oct 2012
Sept 2012
Sept 2012
Aug 2012
Oct 2011
Oct 2011

Apr 2011

